Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-free Pharmacotherapy for Smoking Cessation in TIA/Stroke Patients
NCT00962988Phase 4Completed
- Sponsor
- University of Ottawa Heart Institute
- Start
- Dec 2009
- Primary completion
- Apr 2015
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicotine patch, bupropion and varenicline in Tobacco Use Disorder (TUD) (2 arms), sponsored by University of Ottawa Heart Institute. Primary endpoint: Biochemically Confirmed Continuous Abstinence at 52 weeks. Started Dec 2009; status: completed.
02
Drugs
nicotine patchbupropionvarenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00962988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962988.